Canadian biotech Cyclica has embarked on a multi-phase collaboration with Bayer aimed at the advancement of drug discovery using AI-augmented technologies. The partnership will see Cyclica use Ligand Express, its cloud-based proteome screening platform, to explore off-target profiles of small molecules and deploy advanced AI technology to develop innovative predictive models for pharmacokinetic properties. “Biotech’s mission is to make life better by making it easier for people around the world to live longer, healthier lives,” said Dr. David Sinclair, CEO of Cyclocica.
Canadian biotech Cyclica has embarked on a multi-phase collaboration with Bayer aimed at the advancement of drug discovery using AI-augmented technologies. The partnership will see Cyclica use Ligand Express, its cloud-based proteome screening platform, to explore off-target profiles of small molecules and deploy advanced AI technology to develop innovative predictive models for pharmacokinetic properties. It will also use its Differential Drug Design technology for multi-targeted drug design.